Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 33 min ago
Peer-reviewedCC BYFrontiers in cell and developmental biology

Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety

  • Jiaxin Chen1
  • Juntong Shen1
  • Xiaolin Fu1
  • Min Jiang1
  • Ruihao Liu1
  • Qiang Qiao1
  • Yizhe Hu1
  1. 1Ansteel Group General Hospital , ,
Read full textPDFDOICite

Abstract

Natural killer (NK) cell-based immunotherapy has become a research focus in cellular immunotherapy in recent years,which has advanced rapidly in the treatment of solid tumors. NK cells are key effector cells of innate immunity and can kill abnormal target cells without prior sensitization. A broad consensus holds that NK cell-based immunotherapy may become a new strategy for solid tumor treatment with lower risk and lower cost than T-cell-based immunotherapy. However, its translation from theory to clinical application remains constrained by relevant risks, and research on its cardiovascular safety is still largely absent. This review summarizes the latest research progress of NK cell-based immunotherapy in solid tumors and discusses its cardiovascular safety.

Related

  1. 563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion
    Jing Chen, Fei Wang, Shanshan Wang +10
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  2. Progress in flame-retardant solid-state electrolytes for battery safety and sustainability
    Chijie Ding, Weidu Li, Jiayao Zhou +4
    Cell Reports SustainabilityPeer-reviewedCC BYFull textEcologyEnvironmental science & pollutionDOAJ
  3. Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy
    Marie‐lee Simard, Camille Braun, Éloise Antony +10
    AllergyPeer-reviewedCC BY-NCFull textImmunologyHAL
  4. Connectionist models of human language processing : Progress and prospects
    Morten H. Christiansen, Nick Chater A
    UCL Discovery (University College London)Peer-reviewedLicence not stated27 citedNeuroscienceOpenAlex
  5. Progress and perspectives on DNA-enabled architectures for energy storage and conversion
    Anjana Puthanpurayil Jayarajan, Samanth Kokkiligadda, Soong Ho Um
    iSciencePeer-reviewedCC BY 4.0Systems & synthetic biologyCell PressCrossref

Cite

BibTeXRIS
BibTeX
@article{chen2026progress,
  title = {{Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety}},
  author = {Jiaxin Chen and Juntong Shen and Xiaolin Fu and Min Jiang and Ruihao Liu and Qiang Qiao and Yizhe Hu},
  journal = {Frontiers in cell and developmental biology},
  year = {2026},
  month = oct,
  doi = {10.3389/fcell.2026.1927923},
  url = {https://europepmc.org/article/PMC/PMC13719574},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety
AU  - Jiaxin Chen
AU  - Juntong Shen
AU  - Xiaolin Fu
AU  - Min Jiang
AU  - Ruihao Liu
AU  - Qiang Qiao
AU  - Yizhe Hu
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in cell and developmental biology
DO  - 10.3389/fcell.2026.1927923
UR  - https://europepmc.org/article/PMC/PMC13719574
AB  - Natural killer (NK) cell-based immunotherapy has become a research focus in cellular immunotherapy in recent years,which has advanced rapidly in the treatment of solid tumors. NK cells are key effector cells of innate immunity and can kill abnormal target cells without prior sensitization. A broad consensus holds that NK cell-based immunotherapy may become a new strategy for solid tumor treatment with lower risk and lower cost than T-cell-based immunotherapy. However, its translation from theory to clinical application remains constrained by relevant risks, and research on its cardiovascular safety is still largely absent. This review summarizes the latest research progress of NK cell-based immunotherapy in solid tumors and discusses its cardiovascular safety.
SN  - 2296-634X
ER  -